DE602004027647D1 - An ovarialkrebs beteiligtes protein - Google Patents

An ovarialkrebs beteiligtes protein

Info

Publication number
DE602004027647D1
DE602004027647D1 DE200460027647 DE602004027647T DE602004027647D1 DE 602004027647 D1 DE602004027647 D1 DE 602004027647D1 DE 200460027647 DE200460027647 DE 200460027647 DE 602004027647 T DE602004027647 T DE 602004027647T DE 602004027647 D1 DE602004027647 D1 DE 602004027647D1
Authority
DE
Germany
Prior art keywords
cdcp1
protein involved
ovarial cancer
modulate
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200460027647
Other languages
English (en)
Inventor
Nicola Anne Burgess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma SA
Original Assignee
UCB Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004027647(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Pharma SA filed Critical UCB Pharma SA
Publication of DE602004027647D1 publication Critical patent/DE602004027647D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
DE200460027647 2003-10-22 2004-10-22 An ovarialkrebs beteiligtes protein Active DE602004027647D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0324656A GB0324656D0 (en) 2003-10-22 2003-10-22 A protein involved in ovarian cancer
PCT/GB2004/004502 WO2005042102A1 (en) 2003-10-22 2004-10-22 A protein involved in ovarian cancer

Publications (1)

Publication Number Publication Date
DE602004027647D1 true DE602004027647D1 (de) 2010-07-22

Family

ID=29595617

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200460027647 Active DE602004027647D1 (de) 2003-10-22 2004-10-22 An ovarialkrebs beteiligtes protein

Country Status (11)

Country Link
US (3) US20070009543A1 (de)
EP (1) EP1677875B1 (de)
JP (1) JP4764344B2 (de)
AT (1) ATE470478T1 (de)
AU (1) AU2004285339B2 (de)
CA (1) CA2541846A1 (de)
DE (1) DE602004027647D1 (de)
ES (1) ES2347249T3 (de)
GB (1) GB0324656D0 (de)
PL (1) PL1677875T3 (de)
WO (1) WO2005042102A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007089513A2 (en) * 2006-01-26 2007-08-09 The Trustees Of The University Of Pennsylvania Tumor vasculature markers and methods of use thereof
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
BRPI0813002A2 (pt) 2007-06-29 2017-05-02 Correlogic Systems Inc marcadores preditivos para o câncer ovariano
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
MX2015012566A (es) 2013-03-13 2016-06-06 Fluidic Inc Aditivos sinergicos para celdas electroquimicas con combustible electrodepositado.
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
CN110234348A (zh) 2016-12-16 2019-09-13 蓝鳍生物医药公司 抗-含cub结构域蛋白1(cdcp1)抗体、抗体药物缀合物及其使用方法
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
WO2021132427A1 (ja) 2019-12-27 2021-07-01 株式会社カイオム・バイオサイエンス 抗ｃｄｃｐ１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006698A1 (en) 1998-07-30 2000-02-10 Human Genome Sciences, Inc. 98 human secreted proteins
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
WO2002004508A1 (de) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
CA2516366A1 (en) * 2003-02-19 2004-09-02 Novartis Ag Glycorpotein antigen sima135 expressed in metastatic human tumor cells

Also Published As

Publication number Publication date
US20070009543A1 (en) 2007-01-11
US8263071B2 (en) 2012-09-11
US20130230524A1 (en) 2013-09-05
ES2347249T3 (es) 2010-10-27
US9120860B2 (en) 2015-09-01
JP2007513873A (ja) 2007-05-31
WO2005042102A1 (en) 2005-05-12
AU2004285339A1 (en) 2005-05-12
GB0324656D0 (en) 2003-11-26
PL1677875T3 (pl) 2010-11-30
ATE470478T1 (de) 2010-06-15
JP4764344B2 (ja) 2011-08-31
EP1677875A1 (de) 2006-07-12
US20110059088A1 (en) 2011-03-10
CA2541846A1 (en) 2005-05-12
AU2004285339B2 (en) 2009-11-19
EP1677875B1 (de) 2010-06-09

Similar Documents

Publication Publication Date Title
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20083053L (no) Humane monoklonale antistoffer mot O8E
CY1126007T1 (el) Προαγωγεις αποπτωσης
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201100694A1 (ru) Антитело к cd38 человека и его применение
ATE461220T1 (de) Anti-egfr-antikörper
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
ATE251942T1 (de) Stapelbare statische mischelemente
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
ATE509953T1 (de) Antikörper gegen den erythropoietinrezeptor und verwendungen davon
TR201900764T4 (tr) LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı.
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения

Legal Events

Date Code Title Description
8363 Opposition against the patent